The gut microbiome is emerging as a novel therapeutic target for the treatment of severe mental illness. However, the lack of knowledge on how gut microbiome features can manifest into specific mental health phenotypes is currently limiting the development of therapeutics. In this chapter, I present the evidence suggesting the existence of a gut microbiome-endocannabinoid axis of relevance to anhedonia/amotivation, debilitating symptoms and unmet therapeutic needs in psychotic illness.
Chapter
2022-01-01T00:00:00+00:00
311 - 323
12